1 Title

- 2 Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 infections among
- 3 healthcare personnel in Pakistan: a test-negative, case-control study.

4 Authors:

- 5 Unab I. Khan MBBS, MS.
- 6 Associate Professor, Department of Family Medicine
- 7 Aga Khan University
- 8 PO BOX 3500, Stadium Road campus
- 9 Karachi, Pakistan
- 10
- 11 Imran Hassan, MBBS.
- 12 Senior Instructor, Department of Family Medicine
- 13 Aga Khan University
- 14 PO Box 3500, Stadium Road campus
- 15 Karachi, Pakistan
- 16
- 17 Mahnoor Niaz, MBBS.

- 18 Research Associate, Dean's Clinical Research Fellowship Program
- 19 Aga Khan University
- 20 PO BOX 3500, Stadium Road campus
- 21 Karachi, Pakistan
- 22
- 23 Syed Iqbal Azam, MSc.
- 24 Assistant Professor, Department of Community Health Sciences
- 25 Aga Khan University
- 26 PO Box 3500, Stadium Road campus
- 27 Karachi 74800, Pakistan

28

- 29 Zahra Hasan, PhD.
- 30 Professor, Department of Pathology
- 31 Aga Khan University
- 32 PO Box 3500, Stadium Road campus
- 33 Karachi 74800, Pakistan

34

- 35 Syed Faisal Mahmood, MBBS.
- 36 Associate Professor, Section of Infectious Diseases
- 37 Department of Medicine
- 38 Aga Khan University
- 39 PO Box 3500, Stadium Road campus
- 40 Karachi 74800, Pakistan

41

- 42 Asad Ali MBBS, MPH
- 43 Professor, Department of Pediatrics and Child Health
- 44 Aga Khan University
- 45 PO Box 3500, Stadium Road campus
- 46 Karachi 74800, Pakistan

47

- 48 Corresponding Author:
- 49 Unab I. Khan MBBS, MS.
- 50 Associate Professor, Department of Family Medicine
- 51 Aga Khan University

- 52 PO Box 3500, Stadium Road campus
- 53 Karachi 74800, Pakistan
- 54 Tel: +92 3486 4842
- 55 Email: <u>unab.khan@aku.edu</u>
- 56 Word Count: 2979
- 57 Abstract

Objective During the COVID-19 pandemic, several vaccines that were efficacious in 58 59 randomized controlled trials (RCTs) were authorized for mass vaccination. In developing countries, inactivated vaccines were widely administered. While inactivated vaccines 60 61 have been deemed effective in reducing disease severity, for healthcare personnel 62 (HCPs), effectiveness against COVID-19 infections is also essential to reduce the risk to 63 vulnerable patients and ensure a stable healthcare workforce. In addition, there are 64 limited studies examining inactivated vaccines' effectiveness against emerging SARS-CoV-2 variants in real-world settings. We aimed to estimate the effectiveness of 65 inactivated vaccines (BBIBP-CorV and CoronaVac) against RT-PCR-confirmed COVID-66 67 19 infections among HCPs in the setting of emerging SARS-CoV-2 variants in Pakistan. **Design, setting and participants** A retrospective matched test-negative case-control 68 analysis of existing data of HCPs at a private healthcare system in Pakistan. 69 70 Methods HCPs tested between April 1 and September 30, 2021, were included. Each 71 case was matched to two to six controls by the date of the RT-PCR test (\pm 7 days) to

72	reduce bias. We compared demographics, reasons for testing, and vaccination status
73	between cases and controls using chi-square for categorical variables and t-test for
74	continuous-level data. The odds of getting a PCR-confirmed SARS-COV-2 infection
75	were calculated using conditional logistic regression, after adjusting for age, gender, and
76	work area. Vaccine effectiveness (VE) was calculated as percent VE using (1-OR)*100.
77	Results Inactivated vaccines were ineffective against COVID-19 infections \geq 14 days
78	after receiving the first dose [VE: 20% (95% CI: -10, 41; p=0.162)]. The vaccines
79	showed modest effectiveness \geq 14 days after the second dose against COVID-19
80	infections [VE: 33% (95% CI: 11, 50; p=0.006)], and symptomatic COVID-19 infections
81	[VE: 36% (95% CI: 10, 54; p=0.009)].
82	Conclusions Inactivated vaccines show modest effectiveness against COVID-19
83	infections in the setting of emerging VOCs. This builds a strong case for boosters and/or
84	additional vaccination.

85 Key Words COVID-19; epidemiology; immunology; infection control.

86 INTRODUCTION

87	The coronavirus disease 2019 (COVID-19) pandemic impacted global health, and as of
88	December 9, 2022, more than 657 million COVID-19 cases and six million deaths have
89	been reported to the WHO (1). Mass vaccination remains a cornerstone of public health
90	interventions to counter the COVID-19 pandemic. Several vaccines have proven
91	efficacious in phase III trials and received emergency approval for mass vaccination
92	campaigns (2-4). As healthcare personnel (HCPs) are at a higher risk of contracting the
93	disease and can become a source of infection to vulnerable patients (5, 6), both Centers
94	for Disease Control (CDC) and WHO (World Health Organization) have recommended
95	that national vaccine strategies prioritize vaccination of HCPs (7, 8).
96	In Pakistan, the Government-driven vaccination campaign commenced in February 2021.
97	Vaccines with more than 50% efficacy in clinical trials were approved for mass
98	vaccination by the health regulatory authorities, and HCPs were prioritized for
99	vaccination (9). In the first phase, conventional inactivated vaccines BBIBP-CorV and
100	CoronaVac were administered. Over the next few months, replication-deficient
101	adenovector vaccines, including single-dose Ad5-nCoV (CanSino Bio) and the two-dose
102	ChAdOx1 nCoV-19 (Oxford-AstraZeneca), became available and were administered to
103	HCPs and the public (10).
104	While CoronaVac and BIBP-CorV were efficacious in clinical trials (11, 12) most were
105	conducted before SARS-CoV-2 variants of concern (VOCs) appeared. It, therefore,
106	became crucial to assess the effectiveness of these vaccines in real-world settings during

107	the emergence of VOCs. This information can provide critical insights to help with policy
108	decisions, including the need to give boosters or additional vaccination. We report the
109	effectiveness of BBIBP-CorV and CoronaVac vaccines against RT-PCR-confirmed
110	COVID-19 infections among HCPs, four months into the vaccination drive at a large
111	private healthcare system in Pakistan, with an existing robust employee surveillance
112	system. Our study was conducted in the setting of the third and fourth waves of COVID-
113	19 in Pakistan during which the alpha, beta, gamma, and delta variants were prevalent
114	(13, 14).

115 METHODS

116 Study Design

117 We conducted a matched, test-negative case-control study to evaluate the effectiveness of

118 inactivated vaccines (BBIBP-CorV and CoronaVac) in reducing the odds of RT-PCR-

119 confirmed COVID-19 infections in HCPs. Due to the rapidly changing vaccine uptake

120 and prevalence of the disease in the community, we used the test-negative case-control

121 design as recommended by the WHO (15). Our study population included all HCPs

122 working at AKU who were tested for SARS-CoV-2 by RT-PCR at the AKU Hospital

123 Clinical Laboratories between April 1 and September 30, 2021.

124 De-identified data was transferred from the Employee Health database to STATA v.15.0

125 for analysis. This study was approved by the Ethical Review Committee (ERC#: 2021-

126 5629-18170), AKU.

127 Study Population

128 Inclusion Criteria

129	• HCPs working at AKU and who got an RT-PCR test for SARS-CoV-2 at AKU
130	Hospital Clinical Laboratories between April 1 and September 30, 2021, AND
131	• HCPs who were unvaccinated or vaccinated with one or two doses of BBIBP-
132	CorV or CoronaVac.
133	Exclusion Criteria
134	• HCPs with missing vaccination data.
135	• HCPs who received other vaccines (Ad5-nCoV, AZD1222 (ChAdOx1), mRNA-
136	1273, Janssen (Johnson & Johnson), Gam-COVID-Vac, BNT162b2).
137	• HCPs who were enrolled in COVID-19 vaccine trials.
138	Study Setting
139	The Aga Khan University (AKU), a not-for-profit organization, runs a large healthcare
140	system within Pakistan. Its main campus in Karachi is a 750-bed tertiary care hospital, a
141	medical college, and a nursing school. Additionally, four secondary-care hospitals in two
142	cities, 19 integrated medical centers, and 290 laboratory collection centers in 120 cities
143	across Pakistan are part of the AKU healthcare system. The University employs 13960
144	staff, of which 80% are involved in direct health care (16).

145	Since the beginning of the pandemic, multiple policies were put in place to facilitate
146	HCPs getting tested. Free assessments, testing, and treatment were offered through the
147	Office of Employee Health in the Department of Family Medicine. In addition, time
148	away from work due to quarantine and isolation was not counted from HCPs' annual
149	leaves. For each employee who tested positive, detailed contact tracing was performed.
150	With these employee-friendly policies, HCPs have utilized the Office of Employee
151	Health; to date, 30,000 tests have been conducted.
152	HCPs were tested if: 1) they had symptoms consistent with COVID-19; 2) had a high-risk
153	exposure, as defined by the CDC criteria (17), to a person infected with COVID-19 either
154	in the community or at the workplace; or 3) were part of an outbreak investigation in a
155	specific part of the University. All testing was performed by SARS-CoV-2 polymerase
156	chain reaction on a nasal specimen using the Cobas® 6800 Roche assay (18). The
157	samples were collected at the HCPs' workplace, and all testing was done at the AKU
158	Hospital Clinical Laboratories, accredited by the College of American Pathologists, USA
159	(16).
160	Office of Employee Health maintained a password-protected database for COVID-19-

161 related data that is separate from HCPs' medical records. Once vaccination began, HCPs

also provided dates of vaccine administration and the type of vaccine. Vaccine

163 information was confirmed by verifying with the national database using the SMS-based

164 system developed by the Government of Pakistan (10). Vaccinations were available

without any priority policy to all AKU HCPs, regardless of age, comorbidities, area of
work, previous SARS-CoV-2 infections, etc.

167 **Definitions**

- 168 *Healthcare Personnel*: All employees working within the healthcare system with the
- 169 potential of direct and indirect exposure to patients or infectious material were considered

170 HCPs (19).

- 171 *Case*: HCPs who had a positive SARS-CoV-2 RT-PCR test during the study period and
- 172 had an absence of a positive test result in the preceding 90-day period.

173 *Control:* HCPs with a negative SARS-CoV-2 RT-PCR test result during the study period

and the absence of a positive test result in the preceding 90-day and the subsequent 14-

175 day period.

- *Vaccination Status*: Using the WHO definition (20), we defined vaccination status at thetime of testing as:
- Unvaccinated: If no dose of any vaccine was received.
- Single dose received: If only the first dose of BBIBP-CorV or CoronaVac vaccine
- 180 was received. This group was further divided into two subgroups: a) 0–13 days
- 181 since receiving the first dose; b) \geq 14 days since receiving the first dose of a two-
- 182 dose vaccine.

183	• Two doses received: If both doses of BBIBP-CorV or CoronaVac vaccine were
184	received. This group was also further divided into two: a) 0–13 days since
185	receiving the final dose; b) \geq 14 days since receiving the final dose.
186	COVID-19 Infection: All HCPs who tested positive for SARS-CoV-2 by RT-PCR,
187	regardless of the presence or absence of symptoms.
188	Symptomatic COVID-19: All HCPs who tested positive for SARS-CoV-2 by RT-PCR
189	and had one or more COVID-19-related symptoms in 0-10 days before the RT-PCR test
190	for SARS-CoV-2.
190 191	for SARS-CoV-2. <i>Work Area</i> : HCPs not working in direct clinical care (e.g. laboratory personnel,
191	Work Area: HCPs not working in direct clinical care (e.g. laboratory personnel,
191 192	<i>Work Area</i> : HCPs not working in direct clinical care (e.g. laboratory personnel, housekeeping staff, food providers, and administrative staff) were classified as "non-
191 192 193	<i>Work Area</i> : HCPs not working in direct clinical care (e.g. laboratory personnel, housekeeping staff, food providers, and administrative staff) were classified as "non-clinical"; those providing direct clinical care in areas not designated for patients with

197 Statistical analysis

Data on demographics, results of the SARS-CoV2 RT-PCR test, vaccination status and dates, reason for testing, work area, and previous RT-PCR tests (within the preceding 90day period) were retrieved from the Office of Employee Health's database for statistical analysis. Vaccination status was allocated based on pre-defined definitions stated above.

202	As the study was during the surge, with percent positivity changing weekly, we matched
203	cases and controls by the date of the RT-PCR test (\pm 7 days) to reduce bias. Each case
204	was matched to a minimum of two and a maximum of six controls.
205	We compared demographics, reason for testing, work area and vaccination status
206	between cases and controls using chi-square for categorical variables and t-test for
207	normally distributed continuous-level data. Using unvaccinated individuals as a
208	reference, we used conditional logistic regression to estimate the odds of having RT-
209	PCR-confirmed COVID-19 infections in HCPs vaccinated with a single dose and both
210	doses of the two-dose inactivated vaccines. We calculated unadjusted and adjusted odds
211	ratios, accounting for covariates that included age, sex (using females as a reference), and
212	work area (using non-clinical as a reference). Vaccine effectiveness was calculated as
213	Percent VE using (1- OR)*100. Additionally, we performed a subgroup analysis to assess
214	the effectiveness of vaccines against symptomatic COVID-19 infection.
215	Based on Hitchings et al study (21), we plotted the weekly positivity rate and cumulative
216	vaccine coverage from the time vaccines were introduced (January 2021) to the end of
217	the study period (end of delta surge in September 2021) to understand the impact of
218	vaccines on COVID-19 infections in the healthcare system.
219	Patient and public involvement

220 Patient and the public were not involved in the conduct of this study.

221 **RESULTS**

222	Between April 1 and September 30, 2021, 4599 HCPs were tested for SARS-COV-2 via
223	RT-PCR. Figure 1 shows the process for the selection of HCPs in analysis. After
224	exclusion, 4074 HCPs remained, of whom 1037 tested positive and were classified as
225	cases, and 3037 tested negative and were classified as controls. Of these, 3095 (959 cases
226	and 2136 controls) were tested for symptoms. Cases were matched to controls by the date
227	of the RT-PCR test (\pm 7 days). Each case was matched to two to six controls. No HCPs
228	had to be excluded due to non-matching.
229	Table 1 shows the characteristics of all cases and controls. Compared to controls, cases
230	were older (35.3 ± 9.7 vs. 33.1 ± 8.6 ; p-value < 0.001). 73.9% of cases and 74.8% of
231	controls were administered the BBIBP-CorV vaccine. 61.4% of cases and 60.3% of
232	controls had received the second dose at least 14 days before the test. Among HCPs that
233	had received both doses of vaccine before the RT-PCR test, there was no significant
234	difference in mean duration between the second dose and test between cases and controls
235	$(94.8 \pm 41.6 \text{ vs. } 91.7 \pm 45.1 \text{ days}; \text{ p value}=0.123).$

236 **Table 1**

237 Characteristics of all cases and controls (N=4074)

Characteristics	Cases 1037 (25%)	Controls 3037 (75%)	P-value
Age, years (mean ± SD)	35.3 ± 9.7	33.1 ± 8.6	< 0.001
Age groups, n (%)			
19-29 years	363 (35.0)	1308 (43.1)	
30-39 years	378 (36.5)	1132 (37.3)	
40-49 years	184 (17.7)	411 (13.5)	

50-59 years	96 (9.3)	162 (5.3)	
60 and over	16 (1.5)	24 (0.8)	
Sex, n (%)			
Female	512 (49.4)	1616 (53.2)	0.03
Male	525 (50.6)	1421 (46.8)	
Work area, n (%)			
Non-clinical	307 (29.6)	956 (31.5)	0.001
Clinical non-COVID	673 (64.9)	1813 (59.7)	
Clinical COVID	57 (5.5)	268 (8.8)	
Reason for testing, n (%)			
Outbreak	6 (0.6)	130 (4.3)	
Exposure	72 (6.9)	771 (25.4)	< 0.001
Symptoms	959 (92.5)	2136 (70.4)	
Vaccination status, n (%)			
Unvaccinated	102 (9.8)	314 (10.3)	
Single dose, 0-13 days	18 (1.7)	58 (1.9)	
Single dose, ≥ 14 days	264 (25.5)	762 (25.1)	0.532
Two doses, 0-13 days	16 (1.5)	73 (2.4)	
Two doses, ≥ 14 days	637 (61.4)	1830 (60.3)	
Vaccine name, n (%)			
Unvaccinated	102 (9.8)	314 (10.3)	
BBIBP-CorV	766 (73.9)	2271 (74.8)	0.534
CoronaVac	168 (16.2)	450 (14.8)	
Interval between first dose and RT-PCR	113.5 ± 49.5	114.8 ± 53.9	0.498
test in HCPs with only a single dose of			
vaccine, days (mean \pm SD)			
Interval between second dose and RT-	94.8 ± 41.6	91.7 ± 45.1	0.123
PCR test in HCPs with two doses of			
vaccine, days (mean \pm SD)			

238 SD: standard deviation; RT-PCR: reverse transcription polymerase chain reaction; HCP: health

239 care personnel; IQR: interquartile range

Table S1 describes the characteristics of symptomatic cases and controls (3095/4074

241 (76.0%). There was no significant difference in the mean interval between the onset of

symptoms and the RT-PCR test between cases and controls $(2.1 \pm 2.0 \text{ vs. } 1.9 \pm 2.3 \text{ days};$

243 p=0.017).

244	Table 2 shows the odds of contract	ting COVID-19 infe	ection by the time sine	ce vaccination.
		8		

- After adjusting for age, sex, and work area, we found that a single dose of the two-dose
- vaccines was ineffective within the first 13 days [VE: 30% (95% CI: -26, 62; p=0.234)]
- 247 or even after 13 days had elapsed [VE: 20% (95% CI: -10, 41; p=0.162)]. This shows that
- one dose is not enough to prevent COVID-19 infections. While the vaccines were
- effective during the period < 14 days after the second dose [VE: 44% (95% CI: -2, 69;
- 250 p=0.055)], the results were not significant. The vaccines were most effective \geq 14 days
- after the second dose against a COVID-19 infection [VE: 33% (95% CI: 11, 50;
- 252 p=0.006)].

253 Table 2

254 Effectiveness of inactivated vaccines against all COVID-19 infections (symptomatic

and asymptomatic) (matched case-control)

	Unadjusted analysis		Adjusted analysis*		
	Odds ratio	Р	Odds ratio (95%	Vaccine	P value
	(95% CI)	value	CI)	effectiveness**, %	
				(95% CI)	
N 11		0.000			-0.001
Model		0.098			< 0.001
Unvaccinated	1		1		
Single dose, <	0.76 (0.42,	0.354	0.70 (0.38, 1.26)	30 (-26, 62)	0.234
14 days	1.37)				
Single dose, \geq	0.83 (0.6, 1.12)	0.223	0.80 (0.59, 1.1)	20 (-10, 41)	0.162
14 days					
Two doses, <	0.58 (0.32,	0.069	0.56 (0.31, 1.02)	44 (-2, 69)	0.055
14 days	1.04)				
Two doses, ≥	0.72 (0.54,	0.024	0.66 (0.50, 0.89)	33 (11, 50)	0.006
14 days	0.96)				

256 *: adjusted for age, sex, work area.

257 **: Vaccine Effectiveness= (1-aOR)*100

- 258 Table 3 shows the odds of contracting symptomatic COVID-19 infection by the time
- since vaccination. After adjusting for age, sex, and work area, we found that the first dose
- 260 was ineffective against a symptomatic COVID-19 infection. The vaccines were most
- 261 effective \geq 14 days after the second dose against a symptomatic COVID-19 infection
- 262 [VE: 36% (95% CI: 10, 54; p=0.009)].
- 263 **Table 3**

264 Effectiveness of inactivated vaccines against symptomatic COVID-19 infections

265 (matched case-control)

	Unadjusted analysis		Adjusted analysis*		
	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	Vaccine effectiveness**, % (95% CI)	P value
Model		0.208			< 0.001
Unvaccinated	1		1		
Single dose, < 14 days	0.82 (0.42, 1.57)	0.546	0.71 (0.36, 1.38)	29 (-38, 64)	0.295
Single dose, ≥ 14 days	0.76 (0.53, 1.08)	0.125	0.75 (0.52, 1.07)	25 (-7, 48)	0.101
Two doses, < 14 days	0.60 (0.31. 1.15)	0.122	0.60 (0.31, 1.16)	40 (-16, 69)	0.131
Two doses, ≥ 14 days	0.69 (0.5, 0.96)	0.027	0.64 (0.46, 0.90)	36 (10, 54)	0.009

*: adjusted for age, sex, work area.

267 **: Vaccine Effectiveness= (1-aOR)*100

Figure 2 displays the weekly RT-PCR tests conducted and the cumulative coverage of the

269 first and second dose of inactivated vaccines among HCPs at our institution. We see that

270 despite 75% coverage with 2-doses of inactivated vaccines, we observed an increase in

- 271 positivity rates that correlated with the delta surge in Pakistan. This also shows the
- 272 modest effectiveness of inactivated vaccines against VOCs.

273 **DISCUSSION**

274 Our study among HCPs found that BBIBP-CorV and CoronaVac were not as effective as seen in the efficacy trials (11, 12) in preventing COVID-19 infections, even 14 days after 275 276 the second dose of the two-dose vaccines. Vaccines did not provide significant protection against infection after the first dose and within the first two weeks of the second dose. 277 278 During our study period, the predominant variants in Pakistan switched from alpha, beta 279 and gamma in April to June (13, 14) to the highly transmissible delta constituting up to 99% of the total genomes sequenced from July to September 2021 (22). 280 281 Existing evidence on the effectiveness of inactivated vaccines against infections is 282 inconsistent. Our results agree with a test-negative case-control study conducted in Brazil 283 among healthcare workers during the gamma variant epidemic, which reported modest 284 effectiveness of two doses of CoronaVac, with adjusted effectiveness of 37.1% against 285 symptomatic COVID-19 infections and 37.9% against all COVID-19 infections (21). 286 Similarly, moderate effectiveness against COVID-19 infections was estimated for 287 inactivated vaccines during the delta variant epidemic in China (23, 24). In contrast, the effectiveness estimated in our study is lower than that of CoronaVac reported among 288 289 healthcare workers in Turkey (65%) (25).

290	Several possibilities exist for the lower-than-expected effectiveness of inactivated
291	vaccines in our study. Neutralizing antibody levels correlate with protection against
292	COVID-19 infections (26, 27), and inactivated vaccines produce inferior antibody
293	responses compared to mRNA vaccines (9, 28-30). Moreover, the weakened
294	neutralization potency of inactivated vaccines against the dominant VOCs circulating
295	during our study period, especially the vaccine-resistant delta variant, may have
296	contributed to the limited effectiveness (30, 31). Indeed, studies conducted during the
297	delta variant epidemic have demonstrated only modest effectiveness of two doses of
298	BBIBP-CorV and CoronaVac against infections (23, 32).
299	The mean interval between the second dose of vaccine and COVID-19 infection was
300	more than 90 days in our study. Studies have demonstrated a decline in neutralizing
301	antibody titers three months after vaccinations with the two-dose BBIBP-CorV and
302	CoronaVac (30, 33, 34). It is possible that there was a significant waning of neutralizing
303	antibody responses in our study population. Considering that inactivated vaccines were
304	the most widely used vaccines in low-middle-income countries (LMICs), this finding
305	supports the provision of homologous or heterologous booster doses among recipients of
306	these vaccines.
307	Our study has limitations. Our sample size did not allow us to match more than one

308 variable. However, we did adjust for age, sex, and work area in the logistic model.

309 Additionally, most HCPs in our setting did not get the severe disease or require

310 hospitalization during the study period. Therefore, we cannot comment on vaccines'

311 effectiveness against severe disease. It is, however, essential to note that in healthcare 312 settings, infected HCPs can risk spreading the infection to vulnerable patients. Thus, it is 313 vital to examine not only from the perspective of the infected person but its impact on the 314 system at large. As samples from HCPs in our study population did not undergo genomic 315 sequencing, we could not directly ascertain effectiveness against the circulating VOCs. 316 Finally, our study was conducted on HCPs and the results may not be generalizable to the 317 population outside of healthcare settings. 318 Despite these limitations, our study has clear strengths. Our findings are from a large, 319 well-defined group of HCPs with consistent testing parameters that did not change during 320 the study period. We used RT-PCR which is sensitive to detecting SARS-CoV-2 321 infections (18). Moreover, the vaccine status was highly accurate as it was validated 322 through the national vaccine registry. Using a test-negative design, we mitigated the risk 323 of bias/confounding associated with healthcare access and seeking behavior. Finally, our study was conducted among HCPs whose well-being is imperative to continue to offer 324 325 uninterrupted, quality care to patients in a pandemic. 326 Our study was conducted in an LMIC with a high population density and limited 327 resources. Thus, examining the effectiveness of vaccines in these settings is essential to 328 prevent public health crises. Pakistan and other developing economies with weak 329 healthcare systems need effective vaccines to meet the unprecedented challenge of

dealing with the morbidity and mortality associated with COVID-19. Our study adds new

331 estimates to the effectiveness of these vaccines in HCPs. It may guide future policies in

Pakistan and other LMICs that mainly administered inactivated vaccines in their mass 332 333 vaccination campaigns. By finding complete vaccination with CoronaVac and BBIBP-334 CorV vaccines to be only modestly effective against COVID-19 infections, our study 335 strengthens the case for boosters or additional vaccination among recipients of these 336 vaccines. Additionally, with new variants being identified regularly, it is crucial to 337 prioritize conducting studies at different times and in various settings to continuously 338 examine the effectiveness of these vaccines and boosters against the prevailing variants in 339 real-world settings.

340 CONCLUSIONS

341 Absence of strong effectiveness of inactivated vaccines against COVID-19 infections

among HCPs, especially during the spread of VOCs in our setting is concerning and

343 builds a case for boosters and/or additional vaccination. There is a need for further

344 studies to continuously assess effectiveness in the setting of emerging variants to guide

345 policies regarding boosters to ensure adequate protectiveness.

346 Author Contributions:

- 347 Conception and design: UIK, IH, AA
- 348 Analysis and Interpretation: UIK, IH, IA, MN
- 349 Drafting and Revising manuscript: MN, ZH, SFM, AA, IH, UIK
- 350 Final approval of manuscript: UIK

351 Acknowledgments

- 352 We acknowledge the support of Professor Adil Haider, Dean AKU-Medical College and
- 353 Professor Shahid Shafi, previous CEO of Aga Khan University Hospital, Pakistan. In
- addition, we thank the Employee Health team Shehreen Somani RN, Sania Nawaz RN,
- 355 Noorjehan Momin RN, Dr. Asif Hakim, and the entire Family Medicine team for
- 356 providing care to employees.

357 Ethics Statements

- 358 Participants consent to participate Deidentified data was used for analysis and consent
 359 was not required.
- 360 **Ethics Approval** This study was approved by the Ethical Review Committee (ERC#:
- 361 2021-5629-18170), Aga Khan University.

362 **Competing interests**

- 363 All authors declare no conflicts of interest, support or financial relationship with any
- 364 organization or other activities with any influence on the submitted work.

365 Data availability

- 366 As this is employee-related data, we do not have permission to make it publicly
- 367 accessible. However, data are available from the corresponding author after approval
- 368 from the University's ethics review committee on reasonable request.

369 Funding

- 370 This research received no specific grant from any funding agency in the public,
- 371 commercial or not-for-profit sectors.

372

373 **References**

374 1. WHO Coronavirus (COVID-19) Dashboard: World Health Organization; cited January 9, 2023 [Available from: https://covid19.who.int/. 375 Vovsev M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety 376 2. 377 and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim 378 analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 379 2021;397(10269):99-111. 380 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and 3. 381 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15. 382 Cheng H, Peng Z, Luo W, Si S, Mo M, Zhou H, et al. Efficacy and Safety of COVID-19 4. 383 Vaccines in Phase III Trials: A Meta-Analysis. Vaccines (Basel). 2021;9(6). 384 5. Piccoli L, Ferrari P, Piumatti G, Jovic S, Rodriguez BF, Mele F, et al. Risk assessment 385 and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-386 COVID-19 hospitals in Southern Switzerland. The Lancet Regional Health - Europe. 387 2021;1:100013. 388 Vitrat V, Maillard A, Raybaud A, Wackenheim C, Chanzy B, Nguyen S, et al. Effect of 6. 389 Professional and Extra-Professional Exposure on Seroprevalence of SARS-CoV-2 Infection 390 among Healthcare Workers of the French Alps: A Multicentric Cross-Sectional Study. Vaccines 391 (Basel). 2021;9(8). 392 Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell BP, et al. The 7. 393 Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial 394 Supplies of COVID-19 Vaccine - United States, 2020. MMWR Morb Mortal Wkly Rep. 395 2020;69(49):1857-9. 396 World Health O. WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in 8. 397 the context of limited supply: an approach to inform planning and subsequent recommendations 398 based on epidemiological setting and vaccine supply scenarios, first issued 20 October 2020, 399 latest update 16 July 2021. Geneva: World Health Organization; 2021 2021. Contract No.: 400 WHO/2019-nCoV/Vaccines/SAGE/Prioritization/2021.1. 401 Alqassieh R, Suleiman A, Abu-Halaweh S, Santarisi A, Shatnawi O, Shdaifat L, et al. 9. 402 Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers. 403 Vaccines (Basel). 2021;9(11). 404 COVID-19 Health Advisory Platform by Ministry of National Health Services 10. 405 Regulations & Coordinations GoP. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzag N, et al. Effect of 2 406 11. 407 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A 408 Randomized Clinical Trial. Jama. 2021;326(1):35-45. 409 Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and 12. 410 safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a 411 double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 412 2021;398(10296):213-22. 413 13. Nasir A, Aamir UB, Kanji A, Samreen A, Ansar Z, Ghanchi NK, et al. SARS-CoV-2 414 Variants of Concern (VOC) Alpha, Beta, Gamma, Delta, and Omicron coincident with 415 consecutive pandemic waves in Pakistan. medRxiv. 2022:2022.05.19.22275149.

- 416 14. Hasan Z, Aamir U, Nasir A, Kanji A, Samreen A, Bukhari A, et al. Changing SARS-
- 417 CoV-2 variants in Karachi, Pakistan from alpha to delta through COVID-19 waves three and418 four2021.
- 419 15. WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of
- 420 limited supply: an approach to inform planning and subsequent recommendations based on
- 421 epidemiological setting and vaccine supply scenarios. who.int/publications: World Health
- 422 Organization; 2021 [updated 21 January 2022; cited 2022 13 January 2022]. Available from:
- 423 <u>https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-</u>
 424 vaccines.
- 425 16. AKUH Clinical Laboratory Re-Accredited by the College of American Pathologists for
 426 the Third Time 2022 [Available from:
- 427 <u>https://hospitals.aku.edu/pakistan/AboutUs/News/Pages/re-accreditation-of-akuh-laboratories-</u>
 428 <u>for-the-third-time.aspx</u>.
- 429 17. Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or
- 430 Exposure to SARS-CoV-2: Centers for Disease Control and Prevention; 2020 [updated 21 Jnuary
- 431 202213 January 2022]. Available from: <u>https://www.cdc.gov/coronavirus/2019-</u>
- 432 <u>ncov/hcp/guidance-risk-assesment-hcp.html</u>.
- 433 18. Roche receives FDA authorisation for testing of asymptomatic people with the cobas
- 434 SARS-CoV-2 Test to help control the spread of COVID-19 [press release]. 2021.
- 435 19. Kuhar DT, Carrico R, Cox K, de Perio MA. Infection Control in Healthcare Personnel.
- 436 Appendix 2: Terminology: U.S. Department of Health and Human Services; 2019 [updated437 October 2, 2019.
- 438 20. Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, et al. Evaluation
- 439 of post-introduction COVID-19 Vaccine Effectiveness: Summary of interim guidance of the440 World Health Organization. Vaccine. 2021.
- 441 21. Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, et al.
- 442 Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2
- Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. Lancet RegHealth Am. 2021;1:100025.
- 445 22. Umair M, Ikram A, Rehman Z, Haider SA, Ammar M, Badar N, et al. Genomic diversity
- 446 of SARS-CoV-2 in Pakistan during the fourth wave of pandemic. J Med Virol.
- 447 2022;94(10):4869-77.
- 448 23. Wu D, Zhang Y, Tang L, Wang F, Ye Y, Ma C, et al. Effectiveness of Inactivated
- 449 COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta
- 450 Variant: Real World Study and Evidence China, 2021. China CDC Wkly. 2022;4(4):57-65.
- 451 24. Kang M, Yi Y, Li Y, Sun L, Deng A, Hu T, et al. Effectiveness of Inactivated COVID-19
- 452 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in
- 453 Guangdong, China : A Cohort Study. Ann Intern Med. 2022;175(4):533-40.
- 454 25. Copur B, Surme S, Sayili U, Tuncer G, Pehlivanoglu F, Sengoz G. Effectiveness of
- 455 CoronaVac vaccination against COVID-19 development in healthcare workers: real-life data.
 456 Future Microbiology. 2022;17(17):1381-91.
- 457 26. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
- 458 Neutralizing antibody levels are highly predictive of immune protection from symptomatic
- 459 SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-11.

- 460 27. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al.
- 461 Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine.
- 462 2021;39(32):4423-8.
- 463 28. Mok CKP, Cohen CA, Cheng SMS, Chen C, Kwok KO, Yiu K, et al. Comparison of the
- 464 immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology.
 465 2022;27(4):301-10.
- 466 29. Lim WW, Mak L, Leung GM, Cowling BJ, Peiris M. Comparative immunogenicity of
- 467 mRNA and inactivated vaccines against COVID-19. Lancet Microbe. 2021;2(9):e423.
- 468 30. Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S, et al. Waning immune responses against
- 469 SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine.
- 470 2022;77:103904.
- 471 31. Yu X, Wei D, Xu W, Liu C, Guo W, Li X, et al. Neutralizing activity of BBIBP-CorV
- 472 vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. Nat
 473 Commun. 2022;13(1):1788.
- 474 32. Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P, Suwantarat N,
- 475 Satdhabudha A, et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens
- 476 during the delta variant-dominant pandemic: a test-negative case-control study. Emerg Microbes
- 477 Infect. 2022;11(1):585-92.
- 478 33. Jeewandara C, Aberathna IS, Pushpakumara PD, Kamaladasa A, Guruge D, Wijesinghe
- 479 A, et al. Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine. Immun
 480 Inflamm Dis. 2022;10(6):e621.
- 481 34. Suah JL, Husin M, Tok PSK, Tng BH, Thevananthan T, Low EV, et al. Waning COVID-
- 482 19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study.
- 483 Int J Infect Dis. 2022;119:69-76.
- 484

485

4	86
---	----


487 **Figure Legends:**


488

- 489 **Figure 1**
- 490 Process for the selection of HCPs.
- 491 *Other vaccines: Ad5-nCoV (n=342), AZD1222 (ChAdOx1) (n=60), mRNA-1273 (n=20),
- 492 Janssen (n=1), Gam-COVID-Vac (n=18), BNT162b2 (n=11).

493

- 494 **Figure 2**
- 495 Weekly number of RT-PCR tests conducted and cumulative coverage of inactivated vaccines
- 496 (BBIBP-CorV and CoronaVac) among HCPs at our institution from January 1-September 30,
- 497 2021. Negative and positive RT-PCR tests are represented as red and blue bars, respectively.
- 498 Cumulative coverage of first and second dose of inactivated vaccines is shown by the yellow and
- 499 green lines, respectively. Our study period, April 1-September 30, 2021, is highlighted in pink.





Vaccine Coverage (%)